Advertisement
Screener

Evommune, Inc. (EVMN) Graph

EVMN Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Revenue including tax $0.00; Research and development $26.41M; Operating expenses $34.90M.
  • 2026-03-31: Revenue $0.00; Revenue including tax $0.00; Research and development $17.32M; Operating expenses $23.95M.
  • 2025-12-31: Revenue $0.00*; Revenue including tax (m); Research and development $20.40M*; Operating expenses $29.72M*.
  • 2025-09-30: Revenue $10.00M; Revenue including tax (m); Research and development $19.64M; Operating expenses $23.33M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

EVMN revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$34.90MOperating income-$34.90MOther income, net$2.65MResearch & development$26.41MNet income-$32.25M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$0.00$26.41M$34.90M(m)-$32.25M
2026-03-31$0.00$0.00$17.32M$23.95M$0.00-$21.67M
2025-12-31$0.00*(m)$20.40M*$29.72M*$0.00*-$28.27M*
2025-09-30$10.00M(m)$19.64M$23.33M$0.00-$12.47M
2025-06-30$0.00$0.00$19.64M$22.99M(m)-$13.56M
2025-03-31$3.00M$3.00M$14.36M$18.03M$0.00-$14.56M
2024-09-30(m)(m)$13.29M$16.52M$0.00-$15.92M

Revenue and expense 6 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$0.00$43.73M$58.85M$0.00-$53.92M
2025-06-30$3.00M$3.00M$34.00M$41.03M$0.00-$28.12M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$13.00M$53.64M$64.36M$0.00-$40.60M
2024-09-30$7.00M$46.41M$55.56M$0.00-$46.08M

Revenue and expense 12 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31$13.00M$13.00M$74.04M$94.07M$0.00-$68.87M
2024-12-31$7.00M$7.00M$64.24M$77.01M$0.00-$66.81M

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83